

Review

Emphasizing the vitality of genomics related research in the area of infectious diseases

Wayengera Misaki And Wilson Byarugaba²

¹Research Scientist and PhD Student, ²Head: Division of Human and Molecular Genetics Department of Pathology College of Health Sciences Makerere University P.O Box 7072 Kampala, Uganda

Accepted 31 October, 2007

Sequencing of the human and other species genomes has generated a downstream of sciences that have taken advantage of this knowledge to generate vital links between diseases and genetic variants. Sub-Saharan Africa and many developing countries form the major epicenters for Infectious diseases. Here, the role that genomics may hold in the area of infectious diseases research is emphasized in five blocks: phenotype evaluation studies, evolutionary trends' studies across microbial and host genomes, idiopathic association or host susceptibility studies to disease, therapeutics or vaccine research insights, as well as the development of novel molecular diagnostics.

Key words: Genomics, infectious diseases, HIV/AIDS, malaria, tuberculosis.

INTRODUCTION

The completion of the sequencing of the human (International Human Genome Sequencing Consortium, 2004) has led to the emergence of downstream sciences that have taken advantage of this sequence information such as comparative genomics, transcriptomics, proteomics and metabolomics (Drazen and Phimister, 2007). Consequently, many scientific journals have embraced and embarked on the publication of genome wide related studies. These articles are a major fruit of the human genome and HapMap projects, and they report variants of specific genes, or narrow genomic regions, that are associated with the presence or severity of specific clinical conditions (Drazen and Phimister, 2007).

Majority of the studies published so far have dwelt on the association between genomic variants and various non-infectious diseases most prevalent in the North (Yates et al., 2007; Rennert et al., 2007, Robson and Offit 2007, Mann 2007, Samani et al., 2007; Dunckley et al., 2007; Orrel 2007 and The International Multiple Sclerosis Genetics Consortium, 2007). These studies have for inst-

ance elucidated the association between genomic variants and diseases such as Age-Related Molecular Degeneration (Yates et al., 2007), Breast Cancer (Rennert et al., 2007, Robson and Offit 2007), Heart failure (Mann, 2007), Coronary artery diseases (Samani et al., 2007), Sporadic Amyotrophic Lateral Sclerosis (Dunckley et al., 2007 and Orrel 2007), multiple sclerosis (The International Multiple Sclerosis Genetics Consortium, 2007) and periodic limb movement (Stefansson et al., 2007). In as much as related studies published here as well as elsewhere on part of the infectious diseases (Wormser, 2007; Moalem and Prince, 2007). Breman, (2001) and Carmichael et al. (1996) have elucidated the vital role that genomics may play in the management, control and surveillance of infectious diseases; that emphasis has to an extent remained unfocused. This perspective presents how genomics and its related research may benefit the area of infectious diseases as a specialty.

The rationale for genome related research in the area of infectious diseases

In the period when sequencing of the human genome was on-going human (International Human Genome Sequencing Consortium, 2004), related sequencing of several microbial genomes preceded, paralleled or followed (National Centre for Biotechnology Information, 2007; HIV Sequence database, 2007; Cole et al., 1998; Hoff-

*Corresponding Author E-mail: wmisaki@yahoo.com

Abbreviations: AIDS-Acquired Immunodeficiency Virus; HIV-Human Immunodeficiency Virus; NCBI-National Centre for Bio-technology Information; TB-Tuberculosis.

man et al., 1997; Gardner et al., 1998; Bowman et al., 1999). As of today, several microbial genomes have thus been fully sequenced (National Centre for Biotechnology Information, 2007; Carrington et al 1999), inclusive of the pathogens responsible for the causation of the world's 3 leading infectious causes of morbidity and mortality: the Human Immunodeficiency virus (HIV) (HIV Sequence database, 2007 Casanova et al., 1991), Tubercle bacillus *Mycobacterium* (MTB) (Cole et al., 1998; Cease and Berzofsky, 1994) and plasmodium (Hoffman et al., 1997; Gardner et al., 1998; Bowman et al., 1999; Chen et al., 2000; Chun et al., 1997; Clerici et al., 1994). Approximately 38.6 million [33.4 - 46.0 million] people worldwide were living with HIV by the end of 2005. An estimated 4.1 million [3.4 - 6.2] became newly infected, and 2.8 million [2.4 - 3.3 million] lost their lives to AIDS (UNAIDS 2006; Cohen, 1997). The Human Immunodeficiency virus (HIV) has posed one of the most demanding and yet stiffest challenge in the history of infectious disease vaccine research, mainly because although HIV transmission is in theory largely preventable, in practice, without the development of an effective vaccine, HIV will continue to infect millions throughout the world (Johnson and Kalams, 1998; Graham and Wright, 1995; Cease and Berzofsky, 1994; Haynes, 1996; Cole et al., 1998; Cowman, 2001; Daniel et al., 1998; Dean et al., 1996). On the other hand, the disease tuberculosis (TB) has similarly still posed a great challenge to global human health, with about a third of the world's population, 2 billion carrying the TB bacteria, tubercle bacillus, and 8 - 10 million catching TB disease and 2 million dying from it annually (Snider, 1994; Desrosiers, 1994). The tubercle bacillus belongs to the genus *Mycobacterium*, which comprises a number of Gram-positive, acid-fast, rod-shaped aerobic bacteria and is the only member of the family *Mycobacteriaceae* of the order *Actinomycetales*. Despite the availability of effective short-course chemotherapy (DOTS) and the Bacille Calmette-Guérin (BCG) vaccine, the tubercle bacillus continues to claim more lives than any other single infectious agent. Diagnosis is also made cumbersome by the slow growth and dormancy of the bacillus. The combination of genomics and bioinformatics has the potential to generate the information and knowledge that will enable the conception and development of new therapies and interventions needed to treat this airborne disease and to elucidate the unusual biology of its aetiological agent (Wheeler and Ratledge, 1994; Dorak et al., 2004). Apart from TB and HIV, approximately 40% of the world's population lives in areas where malaria is transmitted. There are an estimated 300 - 500 million cases and up to 2.7 million deaths from malaria each year. The mortality levels are greatest in sub-Saharan Africa, where children under 5 yrs of age account for 90% of all deaths due to malaria (Bremant, 2001; Drazen and Phimister, 2007). Resistance to anti-malarial drugs and insecticides, the decay of public health infrastructure, population movements, political unrest, and environmental changes are

contributing to the spread of malaria (Greenwood and Mutabingwa, 2002; Dunckley et al., 2007). In countries with endemic malaria, the annual economic growth rates over a 25 year period were 1.5% lower than in other countries. This implies that the cumulative effect of the lower annual economic output in a malaria-endemic country was a 50% reduction in the per capita GDP compared to a non-malarious country (Gallup and Sachs, 2001; Duraisingh et al., 2000). Recent studies suggest that the number of malaria cases may double in 20 yrs if new methods of control are not devised and implemented (Gallup and Sachs, 2001; Duraisingh et al., 2000). Despite more than a century of efforts to eradicate or control malaria, the disease remains a major and growing threat to the public health and economic development of countries in the tropical and subtropical regions of the world (Gallup and Sachs, 2001; Duraisingh et al., 2000).

The above pattern, coupled to the health challenges wrought by several other newly emerging (Wormser, 2007; Breman, 2001) and re-emerging pathogens (Moalem and Prince 2007; Carmichael et al., 1996) emphasizes why the area of infectious diseases is wanting for more, and better options; options that genomics and its related research promises to deliver.

How can genomics and genomics related research be explored to benefit the area of infectious diseases as a speciality?

While genomics may not be the solution to all the challenges posed on the scene of global health by infectious diseases, for now, it offers the key to a deeper understanding of the molecular mechanisms of disease; and thus insights into the development of novel therapeutics and diagnostics. The present focus will limit itself; without going in detailed methodologies, to five areas in which it is envisioned genomics related research to play a vital role: phenotype evaluation studies, evolutionary trends' studies across microbial and host genomes, idiopathic association or host susceptibility studies to disease, therapeutics or vaccine research insights, as well as the development of novel molecular diagnostics.

Phenotype evaluation studies and evolutionary trends' studies across microbial and host genomes

Within any microbial species capable of infecting and causing disease (pathogen) in man exist several subtypes with varying replicative and metabolic rates; immune evasion potential; drug resistance profiles and virulence patterns in various host species (Johnson and Kalams, 1998; Graham and Wright, 1995; Cease and Berzofsky, 1994; Haynes, 1996; Snider, 1994; Wheeler and Ratledge, 1994; Qijun et al., 2000; Robinson et al., 2003; Cole et al., 1998; Cowman, 2001; Daniel et al., 1993; Dean et al., 1996; Desrosiers, 1994; Dorak et al., 2004; Faure et al., 2000; Fidock et al., 2000). For instant-

ce, *Plasmodium falciparum* related malaria is associated with more complications than that caused by other *Plasmodium* sp, and exhibits more resistance to the available drugs options. Phenotypes can include various drug resistances and differences in parasite growth and development, virulence, metabolism, gene expression, efficiency of red blood cell invasion and transmission (Robinson et al., 2003; Su and John, 2004; Fidock et al., 2000; Flori et al., 2004). These variations are really a physical expression of a genetic variation, and may be traced and identified with the apparent subtype(s) infecting a patient using genomics related methods: genetic crosses and linkage mapping (Walliker et al., 1987; Smith, J.D., 2004; Gallup and Sachs, 2001; Galvani and Slatkin, 2003), gene association or expression studies (Cowman, 2001; Hayton and Su, 2004; Peterson, 1988; Duraisingh, 2000; Gardner et al., 1998; Gonzalez et al., 2005; Gonzalez et al., 2005; Goudsmit et al., 1991), as well as genome wide population association studies using comparative genomics and DNA microarrays (Mann, 2007; Fidock, 2000; Anderson, 2004; Graham and Wright, 1995). The most studied genes using candidate gene association are probably *pfdfhr*, *pfmdr1* and, more recently, *pfcr1* (Walliker et al., 1987; Gardner et al., 1998). Association of *pfdfhr* mutations with resistance to PY and proguanil in parasite isolates was reported in the late 1980s. Potential association of *pfmdr1* with CQR was described in 1990 (Schwarzer, 1998; Greenwood and Mutabingwa, 2002) but studies from additional field isolates have been controversial, with some declaring a strong association (Duraisingh, 2000; Goudsmit et al., 1997).

Idiopathic association or host susceptibility studies to disease

Several studies have of late emerged demonstrating the association between certain genetic variants and infectious diseases (Fidock et al., 2000; Schwarzer et al., 1998; Paterson et al., 1998; Flori et al., 2003; Casanova et al., 1991; Dean 1996; Frederick et al., 1996; Stephens, 1998; Greenwood, and Mutabingwa, 2002; Haas, 2006; Haynes, 1996; Hayton and Su, 2004; HIV Sequence database 2007; Hoffman et al., 1997; Hu et al., 1996; International Human Genome Sequencing Consortium 2004). For instance, phagocytosis of the Malarial Pigment, hemozoin, Impairs expression of Major Histocompatibility Complex Class II Antigen, CD54, and CD11c in Human Monocytes (Fidock et al., 2000; Greenwood, and Mutabingwa 2002). Major histocompatibility complex (MHC) variations have also been associated with juvenile survival and parasite resistance in a large unmanaged unregulated population, meaning that parasites such as *Plasmodium* are likely to play a major role in the maintenance of MHC diversity in this population (Schwarzer et al., 1998; Haas, 2006). In particular, various clinical pictures of malaria have been associated with variations in MHC, and T cell receptor genes in a series of class I ma-

ior histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide (Paterson et al., 1998; Flori et al., 2003; Haynes, 1996; Hayton and Su, 2004). On the other hand, individuals who are homozygous for a 32-bp deletion in the chemokine-cell receptor gene (*CCR5*) are highly resistant to becoming infected with HIV-1 (Casanova et al., 1991; Dean, 1996; HIV Sequence database, 2007; Hoffman et al., 1997). This *CCR5* "Δ32" variant became established in Europe centuries ago, likely under selective pressure from some other pathogen for example *Yersinia pestis* (Frederick et al., 1996; Hu et al., 1996) or smallpox (Stephens et al., 1998; Galvani and Slatkin, 2003; International Human Genome Sequencing Consortium. 2004; Johnson et al., 1997). Additional human genetic variants reported to influence HIV-1 transmission, viral replication, and/or disease progression include those of the major histocompatibility complex (MHC) genes (Kaslow, 1996; Saah et al., 1998; MacDonald et al., 1998; Carrington et al., 1999; Tang et al., 1999; Keet, 1999; Karacki, 2000; Tang et al., 2002; Liu et al., 2003; Dorak et al., 2004; Johnson and Kalam, 1998; Karacki et al., 2001; Kaslow et al., 1996; Keet et al., 1999; Liu et al., 2003; MacDonald et al., 1998; Mann, 2007; Martin et al., 1998; Martin et al., 2002; Mazzoli et al., 1997), as well as other variants, in the chemokine receptors *CCR5* (Martin et al., 1998; Micahel et al., 1997; Ping et al., 2000; Tang et al., 2002; Tang et al., 2002; McLean and Blower 1993; Michael et al., 1997; Michel et al., 1996; Misaki, 2007; Moalem and Prince, 2007), *CCR2* (Saah, et al., 1998; Karacki et al., 2001), and *CX3CR1* (Faure et al., 2000; Modi et al., 2003), the chemokine-receptor ligands (*CCL5-RANTES*) (An et al., 2002; National Centre for Biotechnology Information (NCBI), 2007), *CCL2 (MCP1)* (Gonzalez et al., 2002; Modi et al., 2003; Orrell, 2007; Peterson et al., 1988), *CCL3L1 (MIP1αP)* (Gonzalez et al., 2005; Paterson et al., 1998), and *CXCL12 (SDF-1)* (Winkler et al., 1998; Perelson et al., 1996), the cytokine *IL10* (Shin et al., 2000; Pinto et al., 1995), a killer immunoglobulin-receptor (*KIR*) gene (Martin et al., 2002; Robson M and Offit 2007), and *APOBEC3G* (Valcke et al., 2004; Robertson et al., 1995). Understanding of these genetic associations in light of clinical disease manifestation, as has been demonstrated for several non-infectious diseases may be well demonstrated and understood using genome wide association studies (International Human Genome Sequencing Consortium, 2004; Drazen and Phimister, 2007; Yates et al., 2007; Rennert et al., 2007; Robson and Offit 2007; Mann, 2007; Samani et al., 2007; Dunckley et al., 2007; Orrell, 2007; The International Multiple Sclerosis Genetics Consortium, 2007; An et al., 2000a; An et al., 2000b; An et al., 2002; Almond et al., 2005; Anderson, 2004; Baba et al., 1995; Blaak et al., 1998; Blower and McLean, 1994; Bolognesi, 1994; Bowman et al., 1999). "Moreover, personalised medicine is increasingly taking advantage of pharmacogenomics to avoid adverse effects. For instance, in the area of HIV care, by way of genomics

pre-screening, the associations that have been replicated in multiple studies between HAART and Genetics can be identified on individual level and the regimens appropriately adjusted to avoid the adverse effects. These include, for example those between (1) abacavir-hypersensitivity reaction and HLA-B*570 (2) efavirenz and nelfinavir pharmacokinetics and the CYP2B6 516G T47, and CYP2C19 681G A polymorphisms, respectively; (3) indinavir- and atazanavir-induced hyperbilirubinemia and a UGT1A1 polymorphism; and (4) nucleoside analogue-associated lipoatrophy and a TNF- polymorphism.

Elucidating novel therapeutics or vaccine research insights

Although the transmission of several infectious diseases is in theory largely preventable, in practice, without the development of effective vaccine, Infectious diseases will still pose a global health threat. For instance, HIV sequence diversity (Valcke et al., 2004; Haas, 2006; Robertson et al., 1995; Perelson et al., 1996; Hu et al., 1996; Goudsmit et al., 1991; Carmichael et al., 1996; Clerici et al., 1994; Pinto et al., 1995; Mazzoli et al., 1997; Blaak et al., 1998; Robertson et al., 1995; Robinson et al., 2003; Samani et al., 2007; The International Multiple Sclerosis Genetics Consortium, 2007; Stefansson et al., 2007; Wheeler and Ratledge 1994; Saah et al., 1998; Schwarzer et al., 1998; Shin et al., 2000; Stephens et al., 1998; Smith et al., 2000), which is a major determinant of antigenic variation, is the biggest of all scientific challenges inclusive of uncertainties surrounding the humoral and mucosal protective immunities (Almond et al., 1995; Johnson et al., 1997; Chun et al., 1997; McLean and Blower, 1993; Blower and McLean, 1994; Desrosiers, 1994; Snider et al., 1994; Su and Wootton 2004; Tang et al., 1999; Tang et al., 2002a; Tang et al., 2002b; Tang et al., 2002c), in-vitro latency or switch off potentials (Daniel et al., 1992; UNAIDS, 2006), safety of trial vaccine candidates (Wyand et al., 1996; Bolognesi, 1994; Valcke et al., 2004; Walliker et al., 1987) and a scarcity ideas for of efficacious options (Bolognesi, 1994; Baba et al., 1995; Wyand et al., 1997; Cohen J, 1997; Walliker et al., 1987; Wyand et al., 1996; Wyand et al., 1997; Wootton et al., 2002). It has now become apparent that an effective HIV vaccine must be representative in terms of immune elicitation to all the antigenic subtypes present within the population its intended for-thus the principle of multivariate vaccines; besides rendering some sort of restriction to the erratic error prone nature of the reverse transcriptase as well as rapid HIV replication rate, in a way arresting the diversity in viral progeny-the basis for recombinant DNA vaccines (Cowman, 2001; Danie et al., 1992). Moreover, newer approaches exploring regenerative strategies such as immune modulation and reconstitution are increasing become promising for an effective anti-HIV vaccine and microbicide (Misaki, 2007; Wormser, 2007). Understanding of the molecular mechanisms of other inf-

ectious diseases like Malaria has in the past been explored to elucidate novel vaccination approaches (Qijun et al., 2000; Robinson et al., 2003; Su and John, 2004; Walliker et al., 1987; Faure et al., 2000; Fidock et al., 2000; Flori et al., 2001; Gallup and Sachs, 2001). The sequencing of several microbial genomes, as was the case for the sequencing of the human (International Human Genome Sequencing Consortium, 2004) must led to the emergence of downstream sciences that will take advantage of this sequence information such as comparative genomics, transcriptomics, proteomics and metabolomics (Drazen and Phimister, 2007; An et al., 2000) to elucidate novel therapeutic and vaccination strategies on the part of infectious diseases.

Development of novel molecular diagnostics

The characteristic features of the tubercle bacillus include its slow growth, dormancy, complex cell envelope, intracellular pathogenesis and genetic homogeneity (Haynes, 1996; Snider, 1994; Dean et al., 1996; Desrosiers, 1994). The generation time of *M. tuberculosis*, in synthetic medium or infected animals, is typically 24 h. This contributes to the chronic nature of the disease, imposes lengthy treatment regimens and represents a formidable obstacle for researchers. The state of dormancy in which the bacillus remains quiescent within infected tissue may reflect metabolic shutdown resulting from the action of a cell-mediated immune response that can contain but not eradicate the infection. As immunity wanes, through ageing or immune suppression, the dormant bacteria reactivate, causing an outbreak of disease often many decades after the initial infection (Snider, 1994; Wheeler, and Ratledge, 1994; Desrosiers, 1994; Dorak et al., 2004). The molecular basis of dormancy and reactivation remains obscure but is expected to be genetically programmed and to involve intracellular signalling pathways (Wheeler and Ratledge, 1994; Desrosiers, 1994). Yet, despite the availability of effective short-course chemotherapy (DOTS) and the Bacille Calmette-Guérin (BCG) vaccine, the tubercle bacillus continues to claim more lives than any other single infectious agent. This is in part due to the evolution of drug resistance, the high prevalence of HIV associated TB, and partly due to this pattern of dormancy adapted by the tubercle bacilli in-vitro (Wheeler and Ratledge, 1994; Dorak et al., 2004). Diagnosis is also made cumbersome by the slow growth and dormancy of the bacillus. The combination of genomics and bioinformatics has the potential to generate the information and knowledge that will enable the conception and development of new therapies and interventions needed to treat this airborne disease and to elucidate the unusual biology of its aetiological agent (Cole et al., 1998; Wheeler and Ratledge, 1994; Cease and Berzofsky 1994; Dorak et al., 2004). The combination of genomics and genomics related research offers hope to the development of novel diagnostics such as DNA microarray, and resistance testing

through gene expression studies as well as linkage disequilibrium (LD) (Wootton et al., 2002; Winkler et al., 1998) and genome wide association studies (Fidock, 2000; Graham and Wright, 1995).

Conclusion

Conclusively, it is widely accepted that genomics and its related sciences has more to offer to infectious diseases especially that which is yet to be explored, but whose exploitation will generate new knowledge vital to reducing the burden of Infectious diseases.

REFERENCES

- An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien S, Winkler CA (2000a). Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. *AIDS* 2000; 14(21): 17–22.
- An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien S, Winkler CA (2000b). Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. *AIDS* 2000; 14(21): 17–22.
- An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D (2002). Modulating influence on HIV/AIDS by interacting RANTES gene variants. *Proc Natl Acad Sci USA*. 99(1000) : 2–7.
- Almond NK, Kent M, Cranage E, Rud B, Clarke E, Stott J. (1995). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. *Lancet* 345: 1342-1344
- Anderson, T.J. (2004). Mapping drug resistance genes in *Plasmodium falciparum* by genome-wide association. *Curr Drug Targets Infect Disord*. 4: 65–78.
- Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM (1995). Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. *Sci*. 267: 1820-1825.
- Blaak H, van't Wout AB, Brouwer M, Cornelissen M, Kootstra NA, Albrecht-van Lent N, Keet RP, Goudsmit J, Coutinho RA, Schuitemaker H (1998) Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-synsytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples. *J. Virol.*, 72: 218-224.
- Blower SM, McLean AR (1994). Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. *Sci*. 265: 1451-1454.
- Bolognesi DP (1994). Not yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1. *J. NIH Research*. 6: 55-62.
- Bowman S, Lawson D, Basham D, Brown D, Chillingworth T, Churcher CM, Craig A, Davies RM, Devlin K, Feltwell T (1999) The complete nucleotide sequence of chromosome 3 of *Plasmodium falciparum*. *Nature* 400: 532–538.
- Breman JG (2001). The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. *Am. J. Trop. Med. Hyg*. 64: 1-11
- Carmichael A, Jin X, Sissons P (1996). Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: Low prevalence of broadly cross-reactive env-specific CTL. *J. Virol*. 70: 8468-8476.
- Carrington M, Nelson NW, Martin MP, Kissner T, Vlahov D, Goedert JJ (1999). HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. *Science* 283(17): 48–52.
- Casanova JL, Romero P, Widmann C, Kourilsky P, Maryanski JL (1991). T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a *Plasmodium berghei* nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. *J. Exp. Med. JEM*. 174: 1371-1383.
- Cease KB, Berzofsky JA (1994). Toward a vaccine for AIDS: The emergence of immunobiology-based vaccine development. *Ann Rev Immunol*. 12: 923-989.
- Chen Q, Schlichtherle M, Wahlgren M (2000). Molecular Aspects of Severe Malaria. *Clin Microbiol Rev*. July. 13(3): 439-450
- Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF (1997). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. *Nature*. 387: 183-187.
- Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, Shearer GM (1994). HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. *JAMA* 271: 42-46.
- Cohen J (1997) Weakened SIV vaccine still kills. *Sci*. 278: 24-25.
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV (1998). Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence.[An erratum appears in *Nature* 396,190] *Nature*. 393: 537-544
- Cowman AF (2001) Functional analysis of drug resistance in *Plasmodium falciparum* in the post-genomic era. *Int.J. Parasitol*. 31: 871–878.
- Daniel MD, Kirchoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. *Sci*. 258: 1938-1941.
- Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study *Sci*. 273: 1856–62.
- Desrosiers RC (1994). Yes it is time to consider use of a live-attenuated virus vaccine against HIV-1. *J NIH Res*. 6: 54-59.
- Dorak M, Tang T, Penman-Aguilar A, Westfall A, Zulu I, Lobashevsky EN, Kancheva M, Schaen, S, Allen R, Kaslow (2004). Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. *Lancet*. 363:2137–9.
- Drzen JM, Phimister EG. (2007). Publishing Genomewide Association Studies. *NEJM* July 18. 357(5):496
- Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szeling S, Joshipura K, Halperin RF (2007). Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis *NEJM* AUG 23rd. 357(8):775-788
- Duraisingh, MT, Roper C, Walliker D, Warhurst DC (2000). Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the *pfmdr1* gene of *Plasmodium falciparum*. *Mol. Microbiol*. 36: 955–961.
- Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, French ALT (2000). Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. *Sci*. 287:2274–7.
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT (2000). Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol. Cell*. 6: 861–871.
- Flori L Sawadogo S, Esnault C, Delahaye NF, Fumoux F, Rihet P (2003). Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. *Hum Mol Genet* Feb 15. 12(4):375-378.
- Gallup JL, Sachs JD (2001). The economic burden of malaria. *Am. J. Trop. Med. Hyg*. 64: 85-96
- Galvani AP, Slatkin M (2003). Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. *Proc. Natl. Acad Sci USA*. 100:15276–9.
- Gardner MJ, Tettelin H, Carucci DJ, Cummings LM, Aravind L., Koonin EV, Shallom S, Mason T, Yu K, Fujii C (1998) Chromosome 2 sequence of the human malaria parasite *Plasmodium falciparum*. *Sci* 282: 1126–1132.
- Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ (2005). The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. *Sci*. 307(14):34–40.

- Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK (2002). HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. *Epub 2002 Oct 8. Proc Natl Acad Sci USA*. 15: 99(21):13795-800.
- Goudsmit J, Back NKT, Nara PL. (1991). Genomic diversity and antigenic variation of HIV-1: Links between pathogenesis, epidemiology and vaccine development. *FASEB J*. 5: 2427-2436.
- Graham BS, Wright PF (1995). Candidate AIDS vaccines. *N. Engl. J Med*. 333: 1331-1339
- Greenwood B, Mutabingwa T (2002). Malaria in 2002. *Nature* 415:670-672
- Haas DW (2006). Human genetic variability and HIV treatment response. *Curr HIV/AIDS Rep*. 3(5): 3-8
- Haynes BF (1996). HIV vaccines: Where we are and where we are going. *Lancet*. 348: 933-937
- Hayton K, Su X.-z. (2004). Genetic and biochemical aspects of drug resistance in malaria parasites. *Curr. Drug. Targets. Infect. Disord*. 4: 1-10.
- HIV Sequence database (2007). HIV-1, HIV-2 and SIV ENV proteins. http://www.hiv.lanl.gov/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html Accessed 18th AUG 2007.
- Hoffman, SL, Bancroft WH, Gottlieb M, James SL, Burroughs ,EC, Stephenson JR, Morgan, M. J (1997) Funding for malaria genome sequencing. *Nature*. 387: 647
- Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, Luo CC (1996). The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. *JAMA*, 275: 210-216.
- International Human Genome Sequencing Consortium (2004). Finishing the euchromatic sequence of the human genome *Nature* 21 October. 431: 931-945
- Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MJ, Desrosiers RC (1997). Induction of vigorous cytotoxic T lymphocyte responses by live attenuated simian immunodeficiency virus. *J Virol*. 71: 7711-7718.
- Johnson RP, Kalams S, (1998). The Science of HIV Vaccine Development. In *HIV InSite Knowledge Base Chapter May*, <http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-02-01-06> Accessed 18th AUG 2007.
- Karacki M, Martin MP, Phair J, Deschenes RMJ, Nelson GR (2001). Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. *N. Engl. J. Med*. 344(16): 68-75.
- Kaslow RA, Carrington M, Apple Park RL, Muñoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL (1996). Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. *Nat Med*. 2(40): 5-11.
- Keet IPM, Tang J, Klein MR, LeBlanc R, Enger C, Rivers C, Apple RJ (1999). Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. *J. Infect. Dis*. 180:299-309.
- Liu G, Carrington M, Kaslow RA, Gao X, Rinaldo CR, Jacobson LP, Margolick JB (2003). Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. *J Infect. Dis*. 187(140): 4-10.
- MacDonald KS, Embree J, Njenga S, Nagelkerke NJ, Ngatia I, Mohammed Z, Barber BH (1998). Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. *J Infect Dis*, 177:551-556.
- Mann DL (2007). MicroRNAs and the Failing Heart *NEJM* July 7th. 356(22):2346-2347
- Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW (1998). Genetic acceleration of AIDS progression by a promoter variant of CCR5. *Science*, 282:1907-1911.
- Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S (2002). Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. *Nat Genet*. 31:429-34.
- Mazzoli S, Trabattoni D, Lo Caputo S, Piconi SBC, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, Clerici M (1997). HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. *Nat. Med*. 3: 1250-1257.
- McLean AR, Blower SM (1993). Imperfect vaccines and herd immunity to HIV. *Proc. R. Soc. Lond B*. 253: 9-13
- Michael NL, Louie LG, Rohrbaugh AL, Dayhoff DE, Wang CE, Sheppard HW. (1997). The role of CCR5 and CCR2 polymorphisms HIV-1 transmission and disease progression. *Nat Med*. 3:1160-1162.
- Michel SF, Libert BJ, Doranz, Joseph R, Corinne L, Claire-Michèle F, Sentob S, Claudine L, Jacqueline C (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature*. 382:722-725.
- Misaki W (2007). A Recombinant Lactobacillus Strain Expressing Genes Coding for Restriction Enzymes Cleaving the HIV Genomes for Use as a Live Microbicide Strategy against Heterosexual Transmission of HIV. *AJUG* 6th, 6(15); 1750-1756
- Moalem S, Prince J. (2007) Survival of the Sickest: A Medical Maverick Discovers Why We Need Disease. In *Survival of the Sickest: A Medical Maverick Discovers Why We Need Disease*. New York, William Morrow. Book review. *NEJM* July 26th; 357(4):427
- Modi WS, Goedert JJ, Strathdee S, Buchbinder, Detels R, Donfield S, O'Brien SJ, Winkler C (2003). MCP-1-MCP-3-eotaxin gene cluster influences HIV-1 transmission. *AIDS*. 17:2357-2365.
- National Centre for Biotechnology Information (NCBI) (2007). 540 Complete Microbial Genomes selected: [A] - 44, [B] - 496 Accessed 21st July 2007. <http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi>
- Orrell RW (2007). Understanding the Causes of Amyotrophic Lateral Sclerosis *NEJM* 2007 Aug 23rd. 357(8):822-823
- Peterson DS, Walliker D, Welles TE (1988). Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. *Proc. Natl. Acad. Sci. USA*. 85: 9114-9118.
- Paterson S, Wilson K., Pemberton JM (1998). Major histocompatibility complex variation associated with juvenile survival and parasite resistance in a large unmanaged ungulate population (*Ovis aries* L.) *Proc. Natl. Acad. Sci. USA* 95: 3714-3719.
- Perelson AS, Neumann AU, Markowitz M, Leonard PM, Ho DD (1996). HIV-1 dynamics *in vivo*: Virion clearance rate, infected cell life-span, and viral generation time. *Sci*. 271:1582-1586.
- Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, Shearer GM (1995). ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. *J. Clin. Invest*. 96: 867-876.
- Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA (2007). Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations *NEJM* July 12th. 357(2):115-123
- Robson M, Offit K. (2007). Management of an Inherited Predisposition to Breast Cancer *NEJM* July 12th. 357:154-162
- Robertson DL, Sharp PM, McCutchan FE, Hahn BH (1995). Recombination in HIV-1. *Nature*. 374: 124-126.
- Obinson BA, Welch TL, Smith JD (2003). Widespread functional specialization of *Plasmodium falciparum* erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome. *Molecular Microbiology* March, 47(5):1265-1278.
- Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ (2007). Genomewide Association Analysis of Coronary Artery Disease *NEJM* Aug 2nd. 357(5):443-453
- The International Multiple Sclerosis Genetics Consortium. (2007) Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study *NEJM* AUG 30th. 357(9):851-862
- Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, Palsson S, (2007). A Genetic Risk Factor for Periodic Limb Movements in Sleep *NEJM* AUG 16th. 357(7):639-647
- Wheeler PR, Ratledge C (1994). In *Tuberculosis: Pathogenesis, Protection, and Control* (ed. Bloom, B. R.) (Am. Soc. Microbiol., Washington DC) 353-385.
- Saah AJ, Hoover DR, Weng S, Carrington M, Mellors J, Rinaldo CR, Mann D (1998). Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute

- HIV-1 infection: Multicenter AIDS Cohort Study. *AIDS*. 12:2107–2113.
- Schwarzer E, Alessio M, Ulliers D, Arese P (1998). Phagocytosis of the Malarial Pigment, Hemozoin, Impairs Expression of Major Histocompatibility. Complex Class II Antigen, CD54, and CD11c in Human Monocytes. *Infect. Immun.* 66(4): 1601-1606
- Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O'Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien SJ, Smith MW (2000). Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. *Proc Natl Acad Sci USA*. 97:19:97(26):14467–14472
- Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C (1998). Dating the origin of the CCR5-Δ32 AIDS-resistance allele by the coalescence of haplotypes. *Am J Hum Genet*, 62:1507–1515.
- Smith JD, Subramanian G, Gamain B, Baruch DI, Miller LH (2000). Classification of adhesive domains in the *Plasmodium falciparum* erythrocyte membrane protein 1 family. *Mol. Biochem. Parasitol.* 110: 293–310.
- Snider DEJ, Raviglione M, Kochi A (1994). In: *Tuberculosis, Pathogenesis, Protection, and Control* (ed. Bloom, B. R.) 2–11 (Am. Soc. Microbiol. Washington DC,
- Su XZ, Wootton JC. (2004). Genetic mapping in the human malaria parasite *Plasmodium falciparum*. *Mol. Microbiol. Sept.* 53 (6): 1573–1582.
- Tang J, Costello C, Keet IPM, Rivers C, Leblanc S, Karita E, Allen S, Kaslow RA. (1999). HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. *AIDS Res. Hum. Retroviruses* 15: 317–324.
- Tang J, Shelton B, Makhataдзе NJ, Zhang Y, Schaen M, Louie LG, Goedert JJ, Seaberg EC, Margolick JB, Mellors J, Kaslow RA (2002a). Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. *J. Virol.* 76(2): 662–672.
- Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA (2002b). Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. *AIDS*, 16:2275–2284.
- Tang J, Wilson CM, Schaen M, Myracle A, Douglas SD, Kaslow RA. (2002c). CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. *AIDS Res. Hum. Retroviruses* 18: 403–412.
- UNAIDS. (2006) Report on the global HIV-AIDS epidemic July.
- Valcke HS, Bernard NF, Bruneau J, Alary M, Tsoukas CM, Roger M (2004). APOBEC3G genetic variants and their influence on the progression to AIDS. *J. Virol.* 78:11070–11076.
- Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT, Corcoran LM, Burkot OR, Carter R (1987) .Genetic analysis of the human malaria parasite *Plasmodium falciparum*. *Science* 236: 1661–1666.
- Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC (1996). Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. *J. Virol.* 70: 3724-3733.
- Wyand MS, Manson KH, Lackner AA, Desrosiers RC et al. (1997). Resistance of neonatal monkeys to live attenuated strains of simian immunodeficiency virus. *Nat Med.* 3: 32-36.
- Wootton, J.C., Feng, X., Ferdig, M.T., Cooper, R.A., Mu J, Baruch DI, et al., (2002). Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*. *Nature* 418: 320–323.
- Wormser GP (2007). Discovery of New Infectious Diseases — Bartonella Species. *NEJM* July 7th; 356(23): 2346-2347
- Winkler C, Modi W, Smith MW, GW Nelson, X Wu, Carrington M, Dean M, Honio T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'brien SJ (1998). Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant: ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). *Science* 279(5349): 389–393
- Yates JRW, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT, the Genetic Factors in AMD Study Group (2007). Complement C3 Variant and the Risk of Age-Related Macular Degeneration *NEJM*, Aug 9th Volume 357(6): 553-561.